Showing results (131-140 of 258) with videos related to
Sort By:
Pageof 26
Cancer|September 20, 2007
Hormone replacement therapy and lung cancer risk in ChineseKuan-Yu Chen, Chin-Fu Hsiao, Gee-Chen Chang, et al.Theranostics|June 7, 2021
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironmentI-Ying Kuo, You-En Yang, Pei-Shan Yang, et al.The Journal of Biological Chemistry|August 4, 2012
Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanismsChi-Yun Wang, Chia-Ling Chen, Yau-Lin Tseng, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 16, 2016
Cost effectiveness of cancer treatment in TaiwanMei-Chuan Hung, Wu-Wei Lai, Helen H W Chen, et al.Oncology|July 12, 2014
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancerYing-Chun Shen, Chung-Pin Li, Chia-Jui Yen, et al.Oncology|July 11, 2013
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II studyChih-Hung Hsu, Yoon Koo Kang, Tsai-Shen Yang, et al.Nature Communications|September 9, 2024
Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancerChun-Hua Hung, Shang-Yin Wu, Cheng-I Daniel Yao, et al.BMC Cancer|July 25, 2024
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II studyMichael Boyer, Rina Hui, Damien Urban, et al.Oncotarget|June 1, 2016
Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancerChia-Sing Lu, Gia-Shing Shieh, Chung-Teng Wang, et al.Cell Death & Disease|October 11, 2023
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic targetShaifali Singh, Nai Yang Yeat, Ya-Ting Wang, et al.Pageof 26